Shoe Zone (SHOE) announced that trading has continued positively throughout July and as a result of this, cash and equivalents as at 25 July 2026 stood at approximately £7.0m ahead of original budget. The Board continues to expect an adjusted loss before tax of no greater than £1.0m for the financial year ending 3 October 2026.
Comment: Although in the current climatic conditions one would expect that people were only buying flip-flops or sandals, it would appear that SHOE is continuing its recovery. Perhaps its outlets have very cold air conditioning, hence attracting the punters? Above the 200 day moving average at 57p we have been and continue to look for May’s 70p area.
BSF Enterprise PLC (BSFA), the biotechnology company focused on developing tissue engineering, lab-grown materials, and bioactive solutions, announced that it has executed Heads of Terms establishing a worldwide, exclusive commercialisation and supply partnership for its proprietary bioactive peptide, ETSYL® (INCI: palmitoyl pentapeptide-87), with SCHAKAU Managementberatung GmbH.
Comment: It is worth including every RNS from BSFA as each one is sure to attract shorting conspiracy / psychotic, crackpot commentary. This is purely designed to bring the company down while pretending it is objective or in the public interest in the form of a PR protection racket. As an anti-dote to this deliberate attempted sabotage, it is worth noting that the shares are up 13% in initial dealings, so someone does find this company exciting, if only for the bioactive peptide.
Thor Explorations Ltd. (THX) provided an operational and financial review for its Segilola Gold mine, located in Nigeria, and for the Company’s mineral exploration properties located in Nigeria and Senegal, for the three months and six months to June 30, 2026. FY2026 production guidance of 75,000 to 85,000 oz maintained, while AISC guidance remains at US$1,000 to US$1,200 per oz.
Comment: The AISC for THX is almost as cheap as driving an armoured van into the front of H Samuel, at near $1,000. It is almost as if this low cost is all that matters. But of course there is plenty more under the bonnet at the sprawling company. After nearly halving from the January peak, the shares are overdue a rebound back to the 70p’s and 80p’s by early autumn.
Helium One Global (HE1), the primary helium explorer in Tanzania with a 50% working interest in the Galactica-Pegasus helium development project in Colorado, USA, noted the Blue Star Helium (ASX:BNL) announcement issued today regarding the Galactica Project:
- The Operator has delivered its third helium trailer from the Pinon Canyon Plant on schedule, with a fourth trailer on site and being filled
- Continued increases in helium output are expected toward the plant’s full design capacity, driven by planned production work, including debottlenecking the plant and gathering system, drilling additional development wells and deepening of existing wells.
Comment: It is just as well that HE1 bought into Galactica, as there does not appear to be much going on in Tanzania. Oh, and there has not been a fundraise for a while (£3.5m in March), shouldn’t there be one soon as investing in other helium companies does not come cheap.
Further to the announcement on 21 May 2026 that Invinity (IES) had been selected to design the world’s largest vanadium flow battery (“VFB”) for FlexBase Group’s Technology Centre Laufenburg (“TZL”) project in Switzerland, Invinity Energy Systems plc (AIM: IES), a global leader in vanadium flow battery technology, is pleased to announce that it has signed an Engineering, Procurement and Construction (EPC) agreement with Equans Switzerland, for the preparation of delivery of the project.
Perhaps a remake of Butch Cassidy and the Sundance Kid is overdue?
Comment: IES shares rose like a homesick angel in May, and this state of affairs could resume, despite the inclusion of the photo above in the RNS. On a technical basis we are assuming the 200 day moving average will hold at 22p and above it a return to the upper 20p’s by the end of next month is possible.
GenIP plc (GNIP), a provider of AI-driven services to help research organisations and corporations commercialise their innovations, announces a number of new and recurring contract wins across its key markets for a total consideration of $87k.
Comment: Right company and business model at the right time, great CEO. Just need to add another zero to the contract size, and another zero to the share price and all will be well with GNIP.
Harena Rare Earths plc (HREE), advancing the Ampasindava ionic clay rare earth project in Madagascar, reported a major regulatory milestone. HREE said “Signing the CCM is a defining regulatory milestone. It gives us a clear framework to advance responsibly in Madagascar and, critically, clears the path to our Proof of Concept pilot plant and onsite laboratory. With the recent DFC facility in place, we are funded to deliver the next phase of work – beginning with the environmental and social assessment, stakeholder engagement and public consultation that underpin our approvals. Before entering commercial production, we will be completing all permits and authorisation consistent with our environmental and social commitments as set out in our PFS.”
Comment: One of the interesting aspects of a company hitting a milestone such as has been announced today by HREE, is that many in the market will not have been aware that the company was actually waiting for this milestone. Nevertheless, with its US Government funding, and highlight proactive Executive Chairman, we would expect year highs for the shares at 4p to be hit once again, and as soon as the end of next month.
Afentra plc (AET), an upstream oil and gas company focused on production and development assets in Africa, provided an operational update on its offshore Angola portfolio, including the Pacassa SW drilling programme, Impala redevelopment programme and operated activities on Block 3/24.
Highlights
Pacassa SW – Successful oil discovery, net pay 136 metres, reservoir quality supports pre-drill estimate of 5000 bopd (gross)
Impala-1 – Production re-established around ~ 3000 bopd (gross) following light well intervention
Impala- 2 – Rig expected to move to Impala-2 post Pacassa SW, results expected end Q4
Block 3/24 – Innovative operating approach reduces survey cost by around 90%
Comment: The good news at AET is that after today’s update it will be awash with bopd’s just at a time and price when it is a good idea to be so. Indeed, Cavendish are calling the shares up to 100p, and it is probably fair to say that at least 90p – the April resistance – could be seen well before 2026 is over.
Hemogenyx Pharmaceuticals plc (HEMO) announced that it has signed a definitive Collaboration Agreement with Cellin Technologies OÜ (“Cellin”), a leading Estonian cell therapy company, for the manufacturing and clinical implementation of the Company’s HG-CT-1 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia (“R/R AML”) under the Hospital Exemption framework in Estonia. The Agreement converts into binding commitments the non-binding Letter of Intent between the parties announced on 23 September 2025 and marks a significant step toward the generation of the Company’s first revenues from HG-CT-1.
Comment: It is perhaps a shame that there are probably only five people in the country who understand the science of what HEMO is trying to achieve. Luckily, as it is still a work in progress this is perhaps not that important. At least the company has been very good at raising cash, and doing it on a regular basis. The last one was £3m in April at £8, versus the share price now at £6.42.
Disclaimer & Declaration of Interest:
The information, investment views, and recommendations in this Zaks Traders Cafe interview are provided for general information purposes only. Nothing in this interview should be construed as a promotion or solicitation to buy or sell any financial product relating to any companies under discussion or referred to or to engage in or refrain from doing so or engage in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion.
